scopolamine + donepezil + PF-04995274 placebo

This is a combination regimen used in clinical research, consisting of three components: scopolamine, donepezil, and a placebo for PF-04995274. Scopolamine is an anticholinergic agent that acts as a muscarinic acetylcholine receptor antagonist and is commonly used to induce transient cognitive impairment in human models of memory dysfunction. Donepezil is an acetylcholinesterase inhibitor approved for the symptomatic treatment of Alzheimer's disease; it works by increasing acetylcholine levels in the brain to improve cognition. The "PF-04995274 placebo" component refers to an inactive substance administered as a control in studies evaluating the effects of PF-04995274, which itself is a 5-hydroxytryptamine (serotonin) receptor 4 (5-HT4) partial agonist developed for cognitive disorders such as Alzheimer's disease[1][3][7]. This specific combination has been used in clinical trials to model or assess drug interactions and cognitive outcomes related to cholinergic and serotonergic modulation[1][5].